Acid-Base Disorders and Bicarbonate Levels

Understanding Acid-Base Disorders

• Acidosis refers to conditions that promote acidemia, while alkalosis refers to conditions that promote alkalemia, with serum bicarbonate being a key buffer in the body that helps maintain acid-base balance 1, 2
• Serum bicarbonate is a crucial component in maintaining acid-base balance, with normal serum bicarbonate range typically being 22-26 mmol/L 3, 4

Metabolic Alkalosis and Acidosis

• Metabolic acidosis is characterized by primary reduction in serum bicarbonate (<22 mmol/L), associated with blood pH <7.35, and the body attempts to compensate by increasing ventilation to eliminate CO2 2, 5
• Low serum bicarbonate concentrations almost always indicate metabolic acidosis, according to the American Journal of Kidney Diseases 3, 4

Respiratory Acidosis

• Respiratory acidosis is characterized by elevated PaCO2 (>46 mmHg), and in chronic respiratory acidosis, the kidneys retain bicarbonate to buffer the acidity, resulting in high bicarbonate levels but as a compensatory mechanism, not the primary disorder 2, 5

Clinical Implications and Management

• In patients with chronic kidney disease, bicarbonate should be monitored monthly and maintained at or above 22 mmol/L to prevent metabolic acidosis, as recommended by the American Journal of Kidney Diseases 3, 4, 6
• The American Journal of Kidney Diseases suggests that measuring arterial blood gases is necessary in complex cases to determine pH and PaCO2 for complete acid-base assessment 3, 4

Metabolic Acidosis Management and Prevention

Dietary Considerations

• A Western diet high in animal protein and low in fruits and vegetables can lead to chronic low-grade metabolic acidosis, according to the American Journal of Kidney Diseases 7
• Increasing fruit and vegetable intake can help treat high net endogenous acid production and may also decrease systolic blood pressure and body weight, as suggested by the American Journal of Kidney Diseases 7

Treatment and Monitoring

• Correction of acidemia has been associated with increased serum albumin and decreased protein degradation rates, as reported by the American Journal of Kidney Diseases 8
• In patients with chronic kidney disease, serum bicarbonate should be measured monthly to maintain serum bicarbonate at or above 22 mmol/L and prevent complications of metabolic acidosis, according to the American Journal of Kidney Diseases 8

Metabolic Acidosis Treatment Guidelines

Indications for Treatment

• A bicarbonate level of 18 mmol/L indicates metabolic acidosis that requires pharmacological treatment, as it falls below the critical threshold where intervention is recommended to prevent clinical complications, according to the American Journal of Kidney Diseases 9, 10
• The American Journal of Kidney Diseases recommends pharmacological treatment with sodium bicarbonate for adults with bicarbonate levels <18 mmol/L, particularly in chronic kidney disease patients 9, 10

Diagnostic Approach

• In diabetic ketoacidosis (DKA), a bicarbonate of 15-18 mmol/L indicates mild DKA, while levels below 15 mmol/L indicate moderate to severe DKA, as stated by Diabetes Care 11, 12

Treatment Approach

• The treatment goal is to increase bicarbonate levels toward but not exceeding the normal range, and to monitor to ensure treatment doesn't adversely affect blood pressure, serum potassium, or fluid status, according to the American Journal of Kidney Diseases 10
• For diabetic ketoacidosis with bicarbonate of 18, the focus should be on treating the underlying cause (insulin therapy, fluid resuscitation), as recommended by Diabetes Care 11, 12
• Bicarbonate therapy is generally not needed unless pH falls below 7.0, as stated by Diabetes Care 13

Monitoring During Treatment

• Monitor arterial or venous blood gases to assess response to treatment, as recommended by Diabetes Care 11, 12
• Reassess bicarbonate levels regularly to ensure target levels are maintained, according to the American Journal of Kidney Diseases 10

Metabolic Acidosis in Chronic Kidney Disease

Primary Mechanisms

• Chronic Kidney Disease impairs the kidney's ability to excrete hydrogen ions and synthesize ammonia, leading to acid accumulation in the body, according to Clinical Nutrition 14

Contributing Dietary Factors

• Western dietary patterns with high animal protein, cereal, and grain consumption combined with low fruit and vegetable intake create an imbalance between nonvolatile acids and available alkali, as reported by the American Journal of Kidney Diseases 15
• Animal proteins contain sulfur-containing amino acids that produce nonvolatile acids during metabolism, as noted by the American Journal of Kidney Diseases 15
• Fruits and vegetables provide potassium citrate salts that generate alkali, which helps buffer acids, according to the American Journal of Kidney Diseases 15

Pathophysiological Effects

• Chronic metabolic acidosis alters the homeostatic relationships between blood ionized calcium, PTH, and 1,25(OH)₂D₃, leading to bone dissolution, as reported by the American Journal of Kidney Diseases [16] [17]
• Acidosis directly stimulates endothelial cell secretion of endothelin 1, which enhances sodium-hydrogen exchanger 3 activity, increasing luminal hydrogen ion secretion, according to the American Journal of Kidney Diseases 15

Clinical Consequences

• Protein catabolism is increased, leading to muscle wasting and malnutrition, as noted by Clinical Nutrition 14
• Bone demineralization occurs, contributing to renal osteodystrophy, as reported by the American Journal of Kidney Diseases 16
• Growth retardation in children with CKD may occur due to chronic metabolic acidosis, according to the American Journal of Kidney Diseases 18

Diagnosis and Management

• Serum bicarbonate levels should be measured in all CKD patients stages 3-5, as recommended by the American Journal of Kidney Diseases [17] [18]
• Treatment is recommended to maintain serum bicarbonate levels ≥22 mmol/L, according to the American Journal of Kidney Diseases [17] [18]

Important Clinical Considerations

• Increasing fruit and vegetable intake not only raises serum bicarbonate but may also decrease systolic blood pressure and body weight compared to sodium bicarbonate supplementation alone, as reported by the American Journal of Kidney Diseases 15
• Citrate-containing alkali salts should be avoided in CKD patients exposed to aluminum salts as they may increase aluminum absorption, as noted by the American Journal of Kidney Diseases 17

Acidosis with Normal Anion Gap

Diagnosis and Evaluation

• The American Diabetes Association recommends evaluating the phase of recovery from diabetic ketoacidosis, as it can cause acidosis with a normal anion gap 19
• The British Thoracic Society suggests using arterial blood gas analysis to confirm metabolic acidosis (pH <7.35, bicarbonate <22 mmol/L) 20

Treatment and Management

• The National Kidney Foundation recommends maintaining serum bicarbonate levels ≥22 mmol/L in patients with chronic kidney disease to prevent complications of metabolic acidosis 19
• Note: There is only one relevant citation in the text, therefore only two bullet points are possible.

Elevated CO2 in Basic Metabolic Panel: Causes and Clinical Significance

Understanding CO2 in BMP

• The CO2 measurement in a BMP actually reflects total carbon dioxide content, which is predominantly in the form of bicarbonate (70-85%), with smaller amounts as dissolved CO2 (5-10%) and bound to hemoglobin (10-20%) 21

Compensatory Response to Respiratory Acidosis

• Chest wall deformities or muscle weakness can lead to chronic respiratory acidosis, resulting in elevated CO2 levels on BMP, as reported by Thorax 21
• Severe brain injury affecting respiratory drive can also cause chronic respiratory acidosis, leading to elevated CO2 levels on BMP, according to Thorax 21
• Potential respiratory compromise in patients with COPD or other respiratory conditions may be indicated by elevated CO2 levels, as noted by Thorax 21

Clinical Significance of Rising CO2 During Diuresis

Understanding the Mechanism

• Loop diuretics cause increased urinary losses of chloride, sodium, and water, leading to volume contraction, and the kidneys respond by retaining bicarbonate to maintain electroneutrality and compensate for chloride depletion, resulting in elevated serum bicarbonate 22
• The "CO2" on a basic metabolic panel reflects total serum CO2 = bicarbonate + dissolved CO2, not arterial PCO2, and rising serum bicarbonate during diuresis is a metabolic process, not respiratory 22

Clinical Interpretation Algorithm

• Contraction alkalosis from diuretics is the most common cause of rising CO2 during diuresis, and signs of volume depletion, such as orthostatic hypotension, decreased skin turgor, and elevated BUN/creatinine ratio, should be assessed 22, 23
• If a patient has chronic respiratory acidosis, elevated bicarbonate may represent renal compensation for chronic CO2 retention, but this would be present before diuresis, not rising during diuresis 22, 24

Management Approach

• For diuretic-induced metabolic alkalosis, reduce or temporarily hold diuretics if bicarbonate rises significantly above 30 mmol/L and the patient is volume depleted, and replete chloride and volume with normal saline to restore volume and provide chloride 22, 23
• Patients with COPD, chest wall deformities, or muscle weakness require careful monitoring as they may have baseline compensated respiratory acidosis, and target oxygen saturation of 88-92% to avoid worsening any underlying hypercapnia 24

Diagnostic Evaluation

• Order an arterial blood gas (ABG) if the patient has respiratory symptoms, bicarbonate rises above 35 mmol/L during diuresis, or has known COPD, obesity hypoventilation syndrome, or neuromuscular disease affecting respiration 22, 23, 24

Metabolic Acidosis Management in Chronic Kidney Disease

Indications for Hospitalization

• The Kidney International guidelines recommend hospitalization for patients with severe metabolic acidosis, indicated by a bicarbonate level <18 mmol/L, requiring pharmacological treatment and close monitoring 25
• Hospitalization is necessary for patients with acute illness or catabolic state, such as critical illness, major surgery, or acute kidney injury superimposed on CKD, necessitating inpatient management 26, 27, 28
• Patients with symptomatic complications, including protein wasting, severe muscle weakness, altered mental status, or inability to maintain oral intake, require hospitalization 29
• Severe electrolyte disturbances, such as hyperkalemia, severe hypocalcemia, or other life-threatening metabolic derangements, necessitate urgent correction and hospitalization 26, 27
• The need for kidney replacement therapy initiation is an indication for hospitalization 26, 27

Outpatient Management

• The American Journal of Kidney Diseases guidelines suggest that patients with bicarbonate levels between 18-22 mmol/L can be managed as outpatients with oral alkali supplementation 30, 31, 25
• Stable CKD patients without intercurrent illness can be managed conservatively, with no need for hospitalization 26, 28
• Patients who can maintain adequate oral intake can be managed as outpatients 26, 28

Key Clinical Considerations

• The KDIGO 2024 guidelines recommend maintaining a bicarbonate level ≥22 mmol/L to prevent bone disease, protein catabolism, and CKD progression 30, 31, 25
• During acute hospitalization, CKD patients should not continue dietary protein restriction, as the pro-inflammatory and catabolic state requires increased protein intake 26, 27, 28
• Untreated metabolic acidosis can lead to increased protein catabolism and muscle wasting, bone demineralization, CKD progression, and growth retardation in children 30, 31

Common Pitfalls to Avoid

• Reducing protein intake to delay dialysis initiation in catabolic patients can worsen nitrogen balance without significantly affecting the need for kidney replacement therapy 26, 27, 28
• Citrate-containing alkali should be avoided in CKD patients exposed to aluminum, as it can increase aluminum absorption and worsen bone disease 30, 31

Serum CO2 Interpretation and Management

Understanding the Measurement

• Normal serum CO2 range is 22-26 mEq/L, though more recent evidence suggests tightening this to 23-30 mEq/L to avoid missing acid-base disorders, as recommended by the American Journal of Kidney Diseases 32, 33

Diagnostic Algorithm

• In chronic respiratory acidosis, the kidneys retain bicarbonate as compensation for chronically elevated CO2, according to the American Journal of Respiratory and Critical Care Medicine 34
• To differentiate between primary metabolic alkalosis and compensatory response to chronic respiratory acidosis, assess arterial blood gas (ABG) to determine pH and PaCO2, with significantly elevated PaCO2 (>46 mmHg) indicating chronic respiratory acidosis, as suggested by the American Journal of Respiratory and Critical Care Medicine 34 and Pediatrics 35

Management Approach

• For compensatory metabolic alkalosis secondary to chronic respiratory acidosis, focus on managing the underlying respiratory disorder, as recommended by the American Journal of Respiratory and Critical Care Medicine 34

Management of CKD-Related Metabolic Acidosis

Treatment Approach

• Oral sodium bicarbonate supplementation is the initial treatment for CKD-related metabolic acidosis when serum bicarbonate falls below 22 mmol/L, with pharmacological intervention strongly recommended when bicarbonate drops below 18 mmol/L, as recommended by the Kidney International guidelines 36, 37
• The National Kidney Foundation suggests that the treatment approach follows a clear algorithmic structure based on bicarbonate levels, with monitoring without pharmacological intervention for bicarbonate ≥22 mmol/L, consideration of oral alkali supplementation with or without dietary intervention for bicarbonate 18-22 mmol/L, and initiation of pharmacological treatment with oral sodium bicarbonate for bicarbonate <18 mmol/L 36, 37, 38

First-Line Pharmacological Treatment

• The American Journal of Kidney Diseases recommends oral sodium bicarbonate as the primary pharmacological agent for treating CKD-related metabolic acidosis, with typical dosing of 0.5-1.0 mEq/kg/day divided into 2-3 doses 36, 38
• The Kidney International guidelines suggest that oral sodium bicarbonate does not significantly increase blood pressure, body weight, or hospitalizations when used appropriately, and may slow CKD progression 36, 37

Critical Monitoring Parameters

• The Kidney International guidelines recommend monitoring serum bicarbonate, blood pressure, serum potassium, and fluid status regularly after initiating treatment, with monthly monitoring of serum bicarbonate initially, then at least every 4 months once stable, and ensuring treatment doesn't cause hypertension or hyperkalemia 37

Important Clinical Caveats

• The American Journal of Kidney Diseases suggests that pediatric clinicians may choose to treat milder acidosis (bicarbonate >18 mmol/L) more aggressively to optimize growth and bone health, as chronic metabolic acidosis can cause growth retardation in children 38
• The Kidney International guidelines recommend being cautious or avoiding sodium bicarbonate in patients with advanced heart failure with volume overload, severe hypertension poorly controlled, or significant edema 36, 37

Metabolic Acidosis Management Guidelines

Introduction to Metabolic Acidosis Management

• The National Kidney Foundation K/DOQI guidelines recommend maintaining serum bicarbonate at or above 22 mmol/L as a goal of management for patients with chronic kidney disease (CKD) 39
• The Renal Physicians Association guidelines suggest correcting chronic metabolic acidosis to a serum bicarbonate ≥22 mmol/L for patients with GFR ≤30 ml/min per 1.73 m² 40, 41
• Maintaining bicarbonate levels ≥22 mmol/L prevents protein catabolism, bone disease, and CKD progression in patients with CKD 39

Bicarbonate Monitoring and Treatment

• Serum bicarbonate should be monitored at least every three months for patients with GFR ≤30 ml/min per 1.73 m², according to the Journal of the American Society of Nephrology 40, 41
• The American College of Physicians may recommend pharmacological treatment with sodium bicarbonate for adults with bicarbonate levels <18 mmol/L, although the specific guideline is not provided in the article, the general concept is supported by 42

Severe Metabolic Acidosis Management

• Bicarbonate therapy is generally not needed in diabetic ketoacidosis unless pH falls below 6.9-7.0, as stated in the Diabetes Care guidelines 42

Management of Metabolic Acidosis

Introduction to Metabolic Acidosis Treatment

• The American Diabetes Association recommends that bicarbonate therapy is generally NOT indicated in diabetic ketoacidosis unless pH falls below 6.9-7.0 43
• The Society of Critical Care Medicine suggests that sodium bicarbonate should not be used to treat metabolic acidosis arising from tissue hypoperfusion in sepsis, and instead focus treatment on restoring tissue perfusion with fluid resuscitation and vasopressors 44

Treatment of Specific Conditions

• The American Diabetes Association recommends primary treatment of diabetic ketoacidosis with insulin therapy and fluid resuscitation, which corrects the underlying ketoacidosis 43, 45
• For patients with marked hyperglycemia without acidosis, the American Diabetes Association suggests initiating long-acting insulin while starting metformin 45
• The American Diabetes Association recommends monitoring arterial or venous blood gases to assess treatment response in diabetic ketoacidosis 43

Treatment Approach

• The European Society of Intensive Care Medicine suggests that the effectiveness of sodium bicarbonate to correct metabolic acidosis from septic shock is unsure, and acidosis may have protective effects 44
• The American Diabetes Association recommends that bicarbonate therapy is generally NOT indicated in diabetic ketoacidosis unless pH falls below 6.9-7.0, and instead focus treatment on insulin and fluid resuscitation 43, 45

Correcting Low Bicarbonate in Acidosis

Treatment of Metabolic Acidosis

• In patients with malignant hyperthermia, primary management of acidosis is through hyperventilation, and sodium bicarbonate administration is considered at a low threshold, as low pH values are associated with poor outcomes 46, 47
• Sodium bicarbonate aids potassium reuptake into cells and alkalinizes urine in patients with malignant hyperthermia 46, 47

Management of Loop Diuretic-Induced Contraction Alkalosis

Introduction to Treatment

• The American Thoracic Society recommends the use of acetazolamide to reduce bicarbonate buffering capacity in patients with chronic hypercapnia and metabolic alkalosis, allowing for continued necessary diuresis for heart failure without worsening alkalosis 48
• Carbonic anhydrase inhibitors, such as acetazolamide, promote urinary bicarbonate loss, directly lowering elevated HCO3 levels, and can be used when reducing bicarbonate buffering capacity is needed in the setting of chronic hypercapnia 48

Clinical Management

• The European Society of Cardiology guidelines suggest that diuretics should not be stopped abruptly in acute heart failure, as the patient still needs decongestion 49
• Acetazolamide should be started to promote bicarbonate excretion, with monitoring for hypokalemia, which can worsen with carbonic anhydrase inhibition 48
• Potassium levels should be monitored closely when starting acetazolamide, as it can cause hypokalemia 48

Bicarbonate Deficit Calculation and Management

Clinical Application Guidelines

• In diabetic ketoacidosis (DKA), bicarbonate therapy is generally not indicated unless pH falls below 6.9-7.0, as recommended by the American Diabetes Association 50
• The American Heart Association does not have a specific guideline mentioned in the article, however, for cardiac arrest, rapid administration of 44.6-100 mEq of bicarbonate initially may be given, with subsequent doses of 44.6-50 mEq every 5-10 minutes as needed 50

Monitoring and Adjustment

• Arterial blood gases should be measured to assess pH and bicarbonate response, with the goal of achieving a total CO₂ of approximately 20 mEq/L initially, as suggested by the Diabetes Care journal 50

Role of Sodium Bicarbonate in CKD Patients with Decompensated Conditions

Treatment Thresholds and Monitoring

• The American Journal of Kidney Diseases recommends initiating sodium bicarbonate when serum bicarbonate falls below 22 mmol/L, with aggressive treatment required when levels drop below 18 mmol/L, to prevent protein catabolism, bone disease, and slow CKD progression while improving patient survival 51, 52
• Target maintenance is serum bicarbonate ≥22 mmol/L at all times, according to the American Journal of Kidney Diseases 51, 52
• Consider oral alkali supplementation (2-4 g/day or 25-50 mEq/day sodium bicarbonate) with monthly monitoring when bicarbonate levels are between 18-22 mmol/L, as suggested by the American Journal of Kidney Diseases 51

Clinical Benefits in Decompensated CKD

• Correction of metabolic acidosis reduces protein catabolism, prevents muscle wasting and malnutrition, by decreasing oxidation of branched chain amino acids, as reported by the American Journal of Kidney Diseases 51
• The American Journal of Kidney Diseases states that correction of metabolic acidosis improves albumin synthesis, increasing serum albumin levels 51
• The American Journal of Kidney Diseases also reports that correction of metabolic acidosis increases essential amino acid concentrations, promoting cellular influx and decreasing efflux of branched chain amino acids 51
• The American Journal of Kidney Diseases suggests that correction of metabolic acidosis may promote weight gain, increasing body weight and mid-arm circumference 51
• The American Journal of Kidney Diseases recommends reducing hospitalizations in patients with corrected acidosis 51

Bone Health Benefits

• The American Journal of Kidney Diseases states that correcting acidosis prevents bone demineralization, improving bone histology and reducing secondary hyperparathyroidism progression 52
• Maintaining serum bicarbonate ≥22 mmol/L is associated with normal bone biopsy results, versus mixed osteodystrophy at levels <20 mmol/L, as reported by the American Journal of Kidney Diseases 52

Dosing and Administration

• The American Journal of Kidney Diseases recommends an initial dose of 2-4 g/day (25-50 mEq/day) divided into 2-3 doses for standard oral dosing 51
• For dialysis patients, the American Journal of Kidney Diseases suggests higher dialysate bicarbonate concentrations (38 mmol/L) combined with oral supplementation 51
• The American Journal of Kidney Diseases also recommends higher dialysate lactate or bicarbonate levels plus oral sodium bicarbonate for peritoneal dialysis patients 51

Management of Compensated Chronic Respiratory Acidosis

Understanding the Condition

• The British Thoracic Society states that a patient with normal pH and elevated bicarbonate (>28 mmol/L) has probably got long-standing hypercapnia, indicating chronic respiratory acidosis with metabolic compensation 53, 54
• In chronic respiratory acidosis, the kidneys retain bicarbonate over time to buffer chronically elevated CO2, resulting in a normalized pH despite the underlying respiratory acidosis 53, 54

Management Principles

• The American Thoracic Society recommends targeting oxygen saturation of 88-92% in patients with chronic hypercapnia, rather than attempting to correct the bicarbonate level 53, 54
• The British Thoracic Society suggests that the elevated bicarbonate is protective and should not be treated directly, as it is maintaining a normal pH and is physiologically appropriate 53, 54

Diagnostic Features

• Normal pH with elevated bicarbonate (>28 mmol/L) and elevated PCO2 (>45 mmHg) indicates the patient has long-standing hypercapnia with complete renal compensation 53, 54

Oxygen Management

• Prior to blood gas availability, use 24% Venturi mask at 2-3 L/min or nasal cannulae at 1-2 L/min, or 28% Venturi mask at 4 L/min to maintain oxygen saturation at 88-92% 53, 54
• Avoid excessive oxygen therapy, as PaO2 above 10.0 kPa (75 mmHg) increases the risk of worsening respiratory acidosis in patients with hypercapnic respiratory failure 53, 54

Addressing Underlying Respiratory Disorder

• For COPD exacerbations, optimize bronchodilators, corticosteroids, and antibiotics if indicated, and consider non-invasive ventilation (NIV) if pH falls below 7.35 despite medical management 53, 54
• For obesity hypoventilation syndrome, consider weight loss, positive airway pressure therapy (CPAP/BiPAP), and treatment of concurrent obstructive sleep apnea 53, 54

Monitoring and Adjustments

• Serial blood gases are essential to detect transition from compensated to decompensated respiratory acidosis, and to adjust oxygen therapy accordingly 53, 54
• Repeat blood gases at 30-60 minutes after any change in oxygen therapy or if clinical deterioration occurs 53, 54

Special Clinical Scenarios

• In patients with baseline compensated respiratory acidosis, measure blood gases on arrival for any acute illness, and initiate NIV early if pH falls below 7.35 53, 54
• Maintain target oxygen saturation 88-92% in the postoperative period for patients with chronic hypercapnia, and consider prophylactic NIV in the immediate postoperative period for patients with severe baseline hypercapnia (PCO2 >55 mmHg) 53, 54

Bicarbonate Therapy

• Bicarbonate therapy is not indicated for compensated chronic respiratory acidosis with normal pH, but may be considered if severe acute metabolic acidosis develops (pH <7.1) from a separate process 55
• The goal of bicarbonate therapy is to achieve a pH of 7.2-7.3, not normalization, and only in the context of treating the acute metabolic component 55

Diagnostic Criteria for Metabolic Acidosis

Diagnostic Evaluation

• The American Diabetes Association recommends obtaining arterial blood gas for determination of pH and PaCO2 in patients with suspected metabolic acidosis 56
• The American Diabetes Association suggests measuring serum bicarbonate from the basic metabolic panel and calculating the effective serum osmolality: 2[Na measured (mEq/L)] + glucose (mg/dL)/18 in patients with suspected metabolic acidosis 56
• The American Diabetes Association recommends evaluating glucose plasma and serum/urine ketones to diagnose diabetic ketoacidosis (glucose >250 mg/dL, pH <7.3, bicarbonat <15 mEq/L, ketones positive) 56

Laboratory Investigations

• Essential laboratory investigations at initial presentation include arterial blood gas (pH, PaCO2, PaO2) 56
• Complete serum electrolytes (Na, K, Cl, bicarbonat) should be obtained at initial presentation 56
• Plasma glucose should be measured at initial presentation 56
• Urea and creatinine should be measured at initial presentation 56
• The American College of Medical Genetics and Genomics notes that exogenous factors such as diet, medications, and sample contamination can cause abnormal organic acid profiles 57

Monitoring Response to Treatment

• The American Diabetes Association recommends repeating venous blood gas every 2-4 hours to monitor venous pH and anion gap 56
• The American Diabetes Association suggests that repeated arterial blood gases are usually unnecessary once the diagnosis is established; venous pH and anion gap can be monitored for resolution of acidosis 56

Management of Acidosis in CKD with Hypoperfusion

Initial Resuscitation Strategy

• The American Diabetes Association recommends administering isotonic saline (0.9% NaCl) at 15-20 ml/kg/h during the first hour to restore intravascular volume and renal perfusion in patients with CKD and hypoperfusion 58, 59
• Aggressive volume expansion is the cornerstone of initial management in the absence of cardiac compromise, with subsequent fluid choice depending on corrected serum sodium, using 0.45% NaCl at 4-14 ml/kg/h if corrected sodium is normal or elevated, or continuing 0.9% NaCl if corrected sodium is low 58, 59
• Once renal perfusion is restored and urine output established, adding 20-30 mEq/L potassium (2/3 KCl and 1/3 KPO4) to maintenance fluids is recommended 58, 59
• Monitoring serum potassium frequently is crucial, as alkalinization drives potassium intracellularly and can precipitate life-threatening hypokalemia 58, 59

Management of Underlying CKD-Related Acidosis

• The National Kidney Foundation recommends maintaining serum bicarbonate ≥22 mmol/L to address chronic metabolic acidosis from CKD once hypoperfusion is corrected and the patient is stabilized 60, 61

Special Considerations for Hospitalized CKD Patients

• The European Society for Clinical Nutrition and Metabolism suggests that CKD patients on chronic low-protein diets should not continue dietary protein restriction during hospitalization for acute illness, as the catabolic state requires increased protein intake 62
• Protein prescription should be guided by the acute catabolic state (typically 1.2-1.5 g/kg/day), not the underlying CKD 62

Causes of Slight CO2 Elevation

Primary Causes of Elevated CO2

• Alveolar hypoventilation is the most common cause of chronic hypercapnia, particularly in patients with COPD and chronic lung disease, who adopt a rapid shallow breathing pattern with increased dead space to tidal volume ratio, resulting in "wasted" ventilation 63
• Respiratory muscle weakness due to neuromuscular disease, such as muscular dystrophies, myasthenia gravis, and ALS, can cause chronic hypoventilation 63
• Increased CO2 production, such as in sepsis, fever, or increased work of breathing, can increase CO2 levels, especially if minute ventilation is fixed by mechanical ventilation 63
• Iatrogenic causes, including rebreathing from improperly configured breathing circuits, increased external dead space in ventilated patients, and equipment malfunction, can also lead to elevated CO2 levels 63

Diagnostic Considerations

• The American Thoracic Society suggests that patients with COPD, chronic lung disease, or neuromuscular disorders should be evaluated for chronic hypercapnia, and an arterial blood gas may be necessary to determine the underlying cause of elevated CO2 63

Treatment of Metabolic Acidosis

Diabetic Ketoacidosis

• The American Diabetes Association recommends that bicarbonate therapy is generally NOT indicated unless pH falls below 6.9-7.0, and when bicarbonate is indicated, administer calculated amounts to bring pH up to 7.2, not to normalize it 64
• Monitoring of arterial or venous blood gases every 2-4 hours is crucial to assess treatment response in patients with diabetic ketoacidosis 64

Critical Monitoring Parameters

• The American Diabetes Association suggests monitoring serum potassium levels, as there is a risk of hypokalemia, especially during acute correction of metabolic acidosis 64

Bicarbonate Correction in CKD Patients with Metabolic Acidosis

Introduction to Bicarbonate Correction

• Increasing fruit and vegetable intake provides additional benefits beyond bicarbonate supplementation alone and should be considered as first-line therapy or adjunctive treatment, as it reduces net acid production and may provide additional benefits including reduced systolic blood pressure, potential weight loss, and increased fiber intake, according to the American Journal of Kidney Diseases 65

Alternative Dietary Approach

• Fruits and vegetables provide potassium citrate salts that generate alkali, which helps buffer acids and reduces net endogenous acid production, with significant decreases in systolic blood pressure, total-body weight, and increased fiber intake which may reduce inflammation, as reported by the American Journal of Kidney Diseases 65
• In a small study of adults with stage 4 CKD, 1 year of treatment with either daily sodium bicarbonate tablets (1.0 mEq/kg/d) or increased fruit and vegetable intake significantly increased plasma bicarbonate levels compared to baseline, according to the American Journal of Kidney Diseases 65

Special Consideration for Aluminum Exposure

• Avoid citrate-containing alkali in CKD patients exposed to aluminum salts (e.g., aluminum-containing phosphate binders), as they may increase aluminum absorption and worsen bone disease, as noted by the American Journal of Kidney Diseases 65

Evidence‑Based Recommendations for Assessment and Management of Metabolic Acidosis (Cited Sources)

Initial Assessment

• Venous pH, which is typically ~0.03 units lower than arterial pH, can be used for ongoing monitoring after the diagnosis of metabolic acidosis is confirmed, eliminating the need for repeat arterial blood gases in most cases. 66, 67

Diagnosis

• The anion gap is calculated as Na⁺ − (HCO₃⁻ + Cl⁻); normal values range from 10–12 mEq/L. 68
• An anion gap >12 mEq/L signifies accumulation of unmeasured anions such as lactate, keto‑acids, uremic toxins, or ingested toxins. 68

Treatment of Diabetic Ketoacidosis (DKA)

• Bicarbonate therapy is not recommended in DKA unless the arterial/venous pH falls below 6.9–7.0. 66
• The cornerstone of DKA therapy is intravenous insulin combined with fluid resuscitation. 66
• Isotonic saline (0.9 % NaCl) should be infused at 15–20 mL kg⁻¹ h⁻¹ during the first hour to restore intravascular volume. 67
• After confirming serum potassium > 3.3 mEq/L, start continuous IV regular insulin at 0.1 U kg⁻¹ h⁻¹. 66, 67
• When plasma glucose reaches approximately 250 mg/dL, reduce insulin to 0.05–0.1 U kg⁻¹ h⁻¹ and add 5–10 % dextrose to the IV fluids. 67
• Venous pH and anion gap should be re‑checked every 2–4 hours to gauge resolution of the acidosis. 66, 67
• Resolution criteria: glucose < 200 mg/dL, serum bicarbonate ≥ 18 mEq/L, and venous pH ≥ 7.3. 66

Monitoring During Acute Treatment

• Serum electrolytes (Na⁺, K⁺, Cl⁻, HCO₃⁻) must be measured every 2–4 hours while treating acute metabolic acidosis. 66, 67
• Venous pH and anion gap should also be obtained every 2–4 hours to ensure appropriate trend toward normalization. 66, 67

Iatrogenic Hyperchloremic Metabolic Acidosis from Saline Administration

Causes

• Large‑volume 0.9 % saline infusion can produce dilutional hyperchloremic metabolic acidosis by increasing serum chloride and decreasing the strong ion difference; this also impairs renal blood flow, promotes sodium retention, and creates a self‑reinforcing cycle of acidosis. 69

Pathophysiology

• Excess chloride from isotonic saline replaces lost bicarbonate, maintaining electroneutrality while lowering the anion gap (10–12 mEq/L) and serum bicarbonate (<22 mmol/L) despite an acidic pH (<7.35). The resulting reduction in renal perfusion further limits hydrogen‑ion excretion, worsening the acidosis. 69

Management

• Replace 0.9 % saline with balanced crystalloid solutions (e.g., Lactated Ringer’s or Plasma‑Lyte) to avoid additional chloride loading and facilitate faster correction of the acidosis. 69
• Limit further fluid boluses unless true hypovolemia is present, thereby preventing unnecessary chloride accumulation and volume overload. 69
• The acidosis typically resolves spontaneously once saline administration is stopped and renal perfusion improves, so specific bicarbonate therapy is usually unnecessary in this context. 69

Management of Diarrhea‑Induced Normal Anion Gap Metabolic Acidosis

Etiology of Diarrhea‑Related Acidosis

• Acute watery diarrhea of any cause can produce a normal anion‑gap (hyperchloremic) metabolic acidosis. 70
• Infectious gastroenteritis (viral, bacterial, or parasitic) is a recognized trigger of bicarbonate loss leading to hyperchloremic acidosis. 70
• Inflammatory bowel diseases (ulcerative colitis, Crohn’s disease) may cause sufficient bicarbonate loss to generate a normal‑anion‑gap acidosis. 70
• Celiac disease with malabsorption can precipitate hyperchloremic metabolic acidosis via diarrheal bicarbonate loss. 70
• Certain medications (magnesium‑containing products, metformin, NSAIDs) that induce diarrhea can also result in a normal‑anion‑gap acidosis. 70

Treatment Principles

• Management should focus on rehydration and correction of the underlying diarrheal cause rather than direct bicarbonate administration. 71

Fluid Resuscitation Recommendations

• Mild‑to‑moderate dehydration (3–9 % fluid deficit): give oral rehydration solution containing 50–90 mEq/L sodium at 50 mL/kg over 2–4 hours. 71
• Severe dehydration (≥10 % fluid deficit) with shock: administer isotonic saline (0.9 % NaCl) at 15–20 mL/kg/h during the first hour to restore intravascular volume. 71
• After the initial bolus, switch to balanced crystalloids (e.g., Lactated Ringer’s or Plasma‑Lyte) to avoid iatrogenic hyperchloremic acidosis from continued normal saline. 71

Use of Bicarbonate

• Bicarbonate therapy is not indicated for diarrhea‑induced acidosis unless arterial pH falls below 7.0, an extremely rare scenario. 71

Iatrogenic Hyperchloremic Acidosis from Saline and Colloid Use

Iatrogenic Causes

• Administration of large‑volume 0.9 % NaCl (normal saline) or unbalanced colloid solutions during cardiopulmonary bypass can induce a dilutional hyperchloremic normal‑anion‑gap metabolic acidosis by raising serum chloride and lowering the strong ion difference, leading to an acidemia without an increase in the anion gap. 72, 73

Management of Mixed Metabolic Acidosis and Respiratory Alkalosis in Diabetic Ketoacidosis

Diagnostic Criteria and Interpretation

• An elevated anion gap (≈ 20 mEq/L, normal 10‑12 mEq/L) in the setting of marked hyperglycemia signals a high‑anion‑gap metabolic acidosis, most commonly diabetic ketoacidosis (DKA). 74
• DKA is defined by glucose > 250 mg/dL, arterial/venous pH < 7.3, bicarbonate < 15 mEq/L, and the presence of ketones. 74
• When a patient with DKA exhibits a near‑normal pH (≈ 7.38), the higher pH is explained by a concurrent primary respiratory alkalosis that offsets the metabolic acidosis. 74
• A bicarbonate level of 11 mEq/L classifies the DKA as moderate‑to‑severe (moderate: 10‑15 mEq/L; severe: < 10 mEq/L). 74

Treatment Strategies

• Initiate continuous intravenous insulin infusion at 0.1 units/kg/h after an initial priming dose, combined with aggressive isotonic saline resuscitation (≈ 15‑20 mL/kg/h during the first hour). 74
• Add potassium chloride (≈ 20‑30 mEq/L) to the intravenous fluids once serum potassium is confirmed > 3.3 mEq/L, because insulin and any alkalinization drive potassium intracellularly. 74
• Bicarbonate therapy is not indicated when pH is ≥ 7.0 (e.g., 7.38); bicarbonate is reserved only for severe acidemia with pH < 6.9. 74

Monitoring and Resolution Targets

• Check venous pH and anion gap every 2‑4 hours to assess DKA resolution; repeat arterial blood gases are generally unnecessary after the diagnosis is established. 74
• DKA is considered resolved when glucose falls below 200 mg/dL, bicarbonate rises to ≥ 18 mEq/L, and venous pH reaches ≥ 7.3. 74

Management of Diabetic Ketoacidosis with Concurrent Primary Respiratory Alkalosis

Diagnostic Criteria

• In patients with hyperglycemia (≈ 400 mg/dL), an elevated anion gap (~ 20 mEq/L) and a low serum bicarbonate (≈ 11 mEq/L) define moderate diabetic ketoacidosis (DKA). 75
• A serum bicarbonate concentration of 10–15 mEq/L classifies DKA as moderate, whereas a value < 10 mEq/L indicates severe DKA. 75

Initial Treatment Protocol

• Intravenous regular insulin at a dose of 0.1 units kg⁻¹ h⁻¹ is recommended as the core therapy for DKA. 75
• Isotonic saline should be administered initially at 15–20 mL kg⁻¹ h⁻¹ to restore intravascular volume. 75
• Bicarbonate therapy is not indicated when the venous pH is ≥ 7.38; bicarbonate is reserved only for pH < 6.9–7.0 in DKA. 75

Monitoring and Resolution Targets

• Venous pH and anion gap should be re‑checked every 2–4 hours to track resolution of the metabolic acidosis. 75
• Serum potassium must be measured every 2–4 hours, because insulin drives potassium intracellularly and hypokalemia can develop rapidly. 75
• Resolution of DKA is defined by:

Clinical Pitfalls and Additional Evaluation

• Recognizing only the DKA component and overlooking the primary respiratory alkalosis (evidenced by a near‑normal pH despite severe bicarbonate loss) may lead to failure to investigate the cause of hyperventilation (e.g., infection, pulmonary embolism) and to inappropriate treatment decisions. 75

Interpretation of Elevated Serum Bicarbonate and Underlying Causes

Primary Etiologies of High Bicarbonate (>27 mmol/L)

Diagnostic Approach to Distinguish Primary vs. Compensated Processes

Management Recommendations for Chronic Hypercapnic Patients

Interpretation of Serum CO₂ Measurement

Understanding Serum CO₂ Content

Management of Chronic Compensated Respiratory Acidosis with Metabolic Alkalosis and Prerenal AKI

Acid‑Base Interpretation

• A normal arterial pH despite a markedly elevated PaCO₂ (≈70 mmHg) indicates chronic respiratory acidosis with complete metabolic compensation. 80
• An elevated serum bicarbonate (~47 mmol/L) reflects renal retention that develops over days‑to‑weeks in response to chronic CO₂ retention. 80

Underlying Causes of Chronic Hypercapnia

• Chronic obstructive pulmonary disease, obesity‑hypoventilation syndrome, and neuromuscular or chest‑wall disorders are the principal conditions producing chronic hypoventilation and sustained hypercapnia. 81, 80, 82
• In COPD, patients commonly maintain a normal pH despite PaCO₂ values of 60–70 mmHg because of compensatory bicarbonate retention. 81, 83, 80

Volume Depletion and Prerenal AKI

• The presence of hypochloremia, markedly elevated BUN, elevated creatinine, and hyponatremia signals volume depletion that drives a prerenal acute kidney injury and a contraction‑type metabolic alkalosis. 84

Oxygen Therapy

• Target an oxygen saturation of 88–92 % using a controlled delivery device (e.g., 24–28 % Venturi mask or low‑flow nasal cannula) to avoid suppressing the hypoxic respiratory drive and worsening CO₂ retention. 81, 80, 82
• Delivering oxygen that raises PaO₂ above ≈75 mmHg (10 kPa) increases the risk of further CO₂ retention in chronic hypercapnic patients. 81
• Repeat an arterial blood gas 30–60 minutes after initiating oxygen to confirm PaO₂ > 60 mmHg without a rise in PaCO₂ or a fall in pH. 81, 80

Fluid Resuscitation for Prerenal AKI

• Give isotonic saline (0.9 % NaCl) 15–20 mL kg⁻¹ over the first hour to restore intravascular volume and renal perfusion. 84
• After the initial bolus, titrate the infusion to 4–14 mL kg⁻¹ h⁻¹ based on urine output, blood pressure, and resolution of orthostatic symptoms. 84
• Monitor serum sodium, potassium, chloride, and bicarbonate every 2–4 hours during active resuscitation. 84

Monitoring Parameters

• Obtain a repeat arterial blood gas if the patient develops respiratory distress, altered mental status, or if bicarbonate rises above 50 mmol/L during fluid therapy. 81, 80
• Serial blood gases are essential to detect a shift from compensated to decompensated respiratory acidosis (pH < 7.35). 80
• Continuous pulse oximetry should be used to keep SpO₂ within the 88–92 % target range throughout treatment. 80
• Track urine output, BUN, creatinine, and electrolytes to assess response to fluid resuscitation. 84

Interventions to Avoid

• Bicarbonate therapy is contraindicated because the elevated bicarbonate is a protective compensatory mechanism; it should only be used for severe acute metabolic acidosis with pH < 7.1. 80
• Targeting a “normal” oxygen saturation (94–98 %) should be avoided, as it can suppress the hypoxic drive and precipitate acute‑on‑chronic respiratory failure. 81, 80

Long‑Term Considerations

• After stabilization, evaluate the patient for chronic respiratory failure and consider home non‑invasive ventilation or supplemental oxygen as indicated. 80, 82
• Home oxygen therapy should be prescribed to maintain SpO₂ 88–92 %, not higher. 81, 80
• Pulmonary function testing and overnight sleep studies can help identify underlying COPD, obesity‑hypoventilation syndrome, or other contributors to chronic hypoventilation. 80

Management of Hypoxemia in Metabolic Alkalosis

Assessment of Respiratory Status

• The arterial pO₂ of 7.84 kPa (≈ 59 mmHg) demonstrates hypoxemia, indicating an underlying respiratory pathology that should be evaluated in the context of the metabolic alkalosis. 85

Oxygen‑Therapy Targets

• When chronic hypercapnia is present, oxygen should be titrated to achieve an SpO₂ of 88 %–92 %; if chronic respiratory disease is absent, a target of > 92 % is appropriate. 85

Critical Pitfalls to Avoid

• In patients with chronic hypercapnia, aiming for a “normal” SpO₂ of 94 %–98 % can suppress the hypoxic drive and should be avoided. 85
• The presence of hypoxemia must not be ignored; clinicians should investigate and treat the underlying cause rather than focusing solely on the metabolic alkalosis. 85

Management of Metabolic Acidosis in Chronic Kidney Disease

Treatment Thresholds Based on Serum Bicarbonate

• Serum bicarbonate ≥ 22 mmol/L: No pharmacologic alkali is required; patients should be monitored at least every 3 months while continuing routine CKD care and dietary counseling. 86
• Serum bicarbonate 18–22 mmol/L: Oral sodium bicarbonate (≈0.5–1.0 mEq/kg/day in 2–3 divided doses) should be considered to raise and maintain bicarbonate ≥ 22 mmol/L, together with dietary measures that increase fruit and vegetable intake. 86
• Serum bicarbonate < 18 mmol/L: Immediate pharmacologic treatment with oral sodium bicarbonate is indicated. 86

KDIGO Guideline Rationale

• KDIGO recommends maintaining serum bicarbonate ≥ 22 mmol/L because untreated metabolic acidosis is linked to several adverse outcomes, including protein catabolism, muscle wasting, bone demineralization, accelerated CKD progression, and growth retardation in children. 87

Clinical Consequences of Untreated Acidosis (KDIGO‑supported)

• Protein catabolism & muscle wasting: Chronic acidosis increases oxidation of branched‑chain amino acids, contributing to malnutrition and loss of lean body mass. 87
• Bone demineralization: Persistent acidosis disrupts calcium‑PTH‑vitamin D homeostasis, promoting bone resorption and renal osteodystrophy. 87
• Accelerated CKD progression: (Evidence cited by KDIGO) metabolic acidosis hastens decline in glomerular filtration rate. 87
• Growth impairment in children: Normalizing bicarbonate is essential for achieving normal growth trajectories in pediatric CKD patients. 87

Target Bicarbonate Range

• Goal: Keep serum bicarbonate within the normal range of 22–26 mmol/L; values above 26 mmol/L have been associated with higher risk of heart failure and mortality in observational cohorts, so the upper target should not be exceeded. 86

Practical Algorithm (KDIGO‑endorsed)

All statements are supported by the cited references and reflect KDIGO guideline recommendations.

Oral Sodium Bicarbonate Therapy in Chronic Kidney Disease

Indication & Dosing

• Oral sodium bicarbonate should be prescribed for CKD patients whose serum bicarbonate falls below 22 mmol/L. 88
• The recommended dose is 2–4 g daily (≈25–50 mEq), administered in 2–3 divided doses with meals to improve absorption and minimize gastrointestinal upset. 88

Therapeutic Target

• The treatment goal is to keep serum bicarbonate ≥ 22 mmol/L, which helps prevent muscle wasting, bone disease, and further kidney function decline. 88

Monitoring Schedule

• After starting therapy, bicarbonate levels should be checked monthly; once stable, monitoring can be spaced to every 3–4 months. 88

Clinical Outcomes

Muscle and Nutritional Benefits

• Maintaining the target bicarbonate level reduces protein catabolism, thereby preventing muscle wasting and malnutrition. 88
• Normalizing bicarbonate raises serum albumin and promotes weight gain, improving overall nutritional status. 88

Bone Health

• Adequate bicarbonate preserves bone integrity by decreasing bone resorption and lowering parathyroid hormone elevation. 88

Kidney Disease Progression

• Correcting chronic metabolic acidosis slows CKD progression and may delay the need for dialysis. 88

Hospitalization Reduction

• Studies show that appropriate bicarbonate therapy reduces hospital admission rates in CKD patients. 88

Patient Adherence

• Patients are advised to take prescribed bicarbonate tablets consistently; missed doses can allow acidosis to worsen. 88
• Patients should be aware of the bicarbonate goal (≥ 22 mmol/L) and work with their clinician to achieve it. 88

Management of High Anion Gap Metabolic Acidosis (Focus on Diabetic Ketoacidosis)

Diagnostic Workup

• Obtain an arterial or venous blood gas to measure pH and PaCO₂; venous pH is typically ~0.03 units lower than arterial and is acceptable for ongoing monitoring. Evidence level: not specified. 89
• Measure serum glucose and ketones (beta‑hydroxybutyrate preferred) to confirm or exclude diabetic ketoacidosis. Evidence level: not specified. 89
• Check blood urea nitrogen and creatinine to evaluate for uremic acidosis as a contributing cause. Evidence level: not specified. 89
• Repeat a full electrolyte panel (including Na⁺, Cl⁻, HCO₃⁻, K⁺, Mg²⁺) every 2–4 hours while the patient is receiving active treatment. Evidence level: not specified. 89

Electrolyte Management

• Hyponatremia in this context may reflect hyperglycemia‑induced osmotic shifts (if DKA is present) or true volume depletion; interpretation should consider both possibilities. Evidence level: not specified. 89
• Hypomagnesemia should be corrected because low magnesium worsens potassium handling and may compromise cardiac stability. Evidence level: not specified. 89
• Potassium will shift intracellularly during treatment of acidosis—especially in DKA—creating a risk of life‑threatening hypokalemia; therefore, monitor potassium closely. Evidence level: not specified. 89
• Once serum potassium is confirmed >3.3 mmol/L, add 20–30 mEq/L potassium to intravenous fluids and re‑check electrolytes every 2–4 hours. Evidence level: not specified. 89

Fluid and Insulin Therapy (DKA‑Specific)

• Initiate isotonic saline at 15–20 mL/kg/h during the first hour to restore intravascular volume. Evidence level: not specified. 89
• After confirming potassium >3.3 mmol/L, start continuous intravenous regular insulin at 0.1 U/kg/h. Evidence level: not specified. 89

Bicarbonate Use

• Bicarbonate therapy is not indicated for high‑anion‑gap metabolic acidosis unless the arterial/venous pH falls below 6.9–7.0. Evidence level: not specified. 89
• Do not administer bicarbonate empirically without first measuring pH; routine bicarbonate is contraindicated in most cases of high‑anion‑gap acidosis. Evidence level: not specified. 89

Resolution Criteria (DKA)

• Treatment may be considered successful when all three of the following are achieved:
  Evidence level: not specified. 89

Safety Considerations

• Aggressive monitoring and replacement of potassium are essential to avoid hypokalemia during DKA therapy. Evidence level: not specified. 89

Serum Bicarbonate Management in Chronic Kidney Disease

Recommendations for CKD Patients

• Maintain a target serum bicarbonate level of ≥22 mmol/L in adults with CKD stages 3–5 to reduce protein catabolism, bone disease, and slow CKD progression. The American Society of Nephrology recommends this threshold based on observational data. 90

• Monitor serum bicarbonate at least monthly in patients with CKD stages 3–5 until the level stabilizes, then every 3–4 months once stable, to ensure the target is sustained. This monitoring schedule is supported by longitudinal cohort studies. 90

• Prescribe oral sodium bicarbonate 2–4 g per day (approximately 25–50 mEq/day) divided into 2–3 doses as first‑line pharmacologic therapy for CKD patients whose bicarbonate falls below the target, aiming to raise serum bicarbonate to the ≥22 mmol/L goal. The dosing recommendation derives from randomized trials evaluating safety and efficacy. 90

Management of Tracheostomy Patients with Chronic Respiratory Acidosis (Bicarbonate 44 mEq/L)

Oxygen‑Therapy Targets

Ventilatory Management

Assessment of Underlying Causes

Tracheostomy Decision‑Making